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ABSTRACT
Background Asthma and chronic obstructive
pulmonary disease (COPD) are chronic inﬂammatory
diseases of the airway. Current treatment options (long
acting β-adrenoceptor agonists and glucocorticosteroids)
are not optimal as they are only effective in certain
patient groups and safety concerns exist regarding both
compound classes. Therefore, novel bronchodilator and
anti-inﬂammatory strategies are being pursued.
Prostaglandin E2 (PGE2) is an arachidonic acid-derived
eicosanoid produced by the lung which acts on four
different G-protein coupled receptors (EP1–4) to cause an
array of beneﬁcial and deleterious effects. The aim of
this study was to identify the EP receptor mediating the
anti-inﬂammatory actions of PGE2 in the lung using a
range of cell-based assays and in vivo models.
Methods and results It was demonstrated in three
distinct model systems (innate stimulus,
lipopolysaccharide (LPS); allergic response, ovalbumin
(OVA); inhaled pollutant, cigarette smoke) that mice
missing functional EP4 (Ptger4
−/−) receptors had higher
levels of airway inﬂammation, suggesting that
endogenous PGE2 was suppressing inﬂammation via EP4
receptor activation. Cell-based assay systems (murine and
human monocytes/alveolar macrophages) demonstrated
that PGE2 inhibited cytokine release from LPS-stimulated
cells and that this was mimicked by an EP4 (but not
EP1–3) receptor agonist and inhibited by an EP4 receptor
antagonist. The anti-inﬂammatory effect occurred at the
transcriptional level and was via the adenylyl cyclase/
cAMP/ cAMP-dependent protein kinase (PKA) axis.
Conclusion This study demonstrates that EP4 receptor
activation is responsible for the anti-inﬂammatory activity
of PGE2 in a range of disease relevant models and, as
such, could represent a novel therapeutic target for
chronic airway inﬂammatory conditions.
INTRODUCTION
Asthma and chronic obstructive pulmonary disease
(COPD) are respiratory diseases with an increasing
global prevalence that represent a social and eco-
nomic burden for both industrialised and develop-
ing countries. The World Health Organization
states that the number of patients with asthma is
300 million and predicts that this ﬁgure will rise to
400 million by 2025,1 while there are 600 million
people with COPD worldwide and the disease is
predicted to be the third ranked leading cause of
death by 2020.1 Exacerbations are common events
in the lives of patients with asthma and COPD.
These episodes are often associated with infections
by viruses or bacteria and cause worsening of
symptoms, which can be fatal. Often these heigh-
tened symptoms are far less responsive to normal
treatments and are associated with increased health-
care costs and societal impact. There is therefore an
urgent need to develop safe and effective therapies
for these respiratory diseases.
It has been recognised for many years that pros-
taglandin E2 (PGE2) is produced by many cell types
within the lung.2 Furthermore, exogenous PGE2
has been shown to have bronchodilator and anti-
inﬂammatory properties in rodent models3 and
human subjects.4 5 Thus, PGE2 could represent an
effective treatment, but it is associated with airway
irritation and coughing6 and has a very short half-
life and, as such, has an inappropriate pharmacoki-
netic proﬁle for general clinical use.
The biological actions of PGE2 are predomin-
antly mediated by the activation of the four EP
receptors, EP1–4.
7 We and others have recently
shown that the bronchodilator properties of PGE2
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Key messages
What is the key question?
▸ Prostaglandin E2 (PGE2) possesses
anti-inﬂammatory and bronchodilator activity in
clinical studies but unfortunately this is
accompanied by airway irritancy, so
identiﬁcation of the receptor mediating the
beneﬁcial effects could lead to the
development of a novel therapeutic for chronic
inﬂammatory diseases characterised by airﬂow
obstruction.
What is the bottom line?
▸ EP4 receptor activation is responsible for the
anti-inﬂammatory activity of PGE2 across a
range of inﬂammatory in vivo models and in
human cell-based assays.
Why read on?
▸ This study identiﬁes for the ﬁrst time in a range
of clinically relevant models the EP4 receptor
and its associated signalling pathway as a
target for a dual bronchodilator/
anti-inﬂammatory therapy for the treatment of
respiratory diseases such as asthma and
chronic obstructive pulmonary disease.
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in human airways are mediated via activation of the EP4 recep-
tor,8 whereas the undesirable triggering of airway sensory
nerves appears to be via its activity at the EP3 receptor.
9
However, it is still not clear which receptor is involved in medi-
ating the anti-inﬂammatory effects of PGE2. Identiﬁcation of a
receptor mediating the anti-inﬂammatory and bronchodilator
effects of PGE2 without the airway irritant activity would
harness the beneﬁcial effects while avoiding the undesirable
properties.
To achieve this aim we proﬁled the inﬂammatory status of EP
receptor knockout (KO) mice in an array of preclinical respira-
tory disease model systems (endotoxin: innate; allergen: asthma-
like; and smoke: COPD-like). To investigate the signalling
mechanisms involved, we used in vitro murine and human cell-
based assay systems. In vitro assays conﬁrmed the in vivo data
which suggested that EP4 receptor activation is responsible for
the anti-inﬂammatory activity of PGE2 and that the effect was at
the level of cytokine gene transcription via an adenylyl cyclase
(AC)/cAMP/cAMP-dependent protein kinase (PKA) axis.
MATERIALS AND METHODS
Role of EP receptors in murine respiratory models
Breeding pairs of C57bl/6 wild type and EP receptor gene
(Ptger1–Ptger4) KO mice were purchased from Harlan (Bicester,
Oxon, UK) and provided by Dr Shuh Narumiya, Kyoto
University, respectively. Ptger1–Ptger3 KO mice were back-
crossed on the C57bl/6 at least eight times. Ptger4−/− mice do
not survive on the C57bl/6 background10 and were backcrossed
on a mixed background of 129/Ola×C57bl/6. Corresponding
wild type colonies were generated. Male mice (18–20 g) were
generated from established breeding colonies maintained intern-
ally. Experiments were performed under Home Ofﬁce project
licence (PPL 70/7212) and procedures adhered to the Animals
(Scientiﬁc Procedures) Act 1986 and according to the ARRIVE
guidelines.11
Mice were challenged with inhaled lipopolysaccharide (LPS)
(innate response), ovalbumin (OVA) (allergic: asthma-like) or
cigarette smoke as previously described.12–14 Brieﬂy, for the
innate response model, mice were challenged with an aerosol of
endotoxin-free saline (for 30 min) or LPS (1 mg/mL,
Escherichia coli serotype 0111:B4). For the asthma model, mice
were sensitised with OVA (intraperitoneally with alum on days 0
and 14) and on days 24, 25 and 26 mice were intranasally chal-
lenged with saline or OVA (50 mg in 50 mL) under isoﬂurane
anaesthesia. For the COPD model, mice were challenged with
cigarette smoke or room air for 1 h twice a day for 3 days.
Airway cellular inﬂammation was assessed via differential count-
ing in the lavage and EP mRNA receptor expression determined
in the lung tissue (over time at 2, 6, 24 and 48 h after ﬁnal
challenge).
Role of EP receptors in cell-based systems
Cultured murine ( J774) and human (THP-1) monocytes
(treated with the cyclo-oxygenase inhibitor indomethacin) were
challenged with LPS in the presence and absence of PGE2.
Cytokine levels in the culture medium were assessed using
ELISA. In parallel experiments, the impact of speciﬁc EP recep-
tor agonists EP1 (ONO-D1-004), EP2 (ONO-AE1-259), EP3
(ONO-AE-248), EP4 (ONO-AE1-329) and antagonists EP2
(PF-04418948) and EP4 (ONO-AE3-208) were studied.
Concentrations used were selected from previous studies and
published literature.8 9 15 Dimethyl sulfoxide was used as the
vehicle, ﬁnal concentration 0.001–2% (v/v). EP receptor
expression was determined in THP-1 cells and primary human
alveolar macrophages by RT-PCR.
Cytokine production was measured at the mRNA (RT-PCR
2 h post-challenge) and protein (ELISA 22 h post-challenge) level
to assess the effect of EP4 agonist on transcription/translation. To
further explore the signalling mechanism, the role of AC (AC
activator: forskolin; inactive control: 1,9 dideoxyforskolin) and
PKA/exchange proteins activated by cAMP (EPAC) (PKA activa-
tor: 6-Bnz-cAMP; EPAC activator: SP-8-pCPT-20-O-Me-cAMP;
and PKA inhibitor: RP-8-CPT-cAMPS) were explored; concen-
trations were selected from published data and unpublished con-
centration–response curves.16 17 The key experiment was
repeated in primary human alveolar macrophages as previously
described.18 Human lung tissue was purchased from the
International Institute for the Advancement of Medicine (Edison,
New Jersey, USA). In all cases, consent for use of the tissue in sci-
entiﬁc research and ethics approval were obtained from the
Royal Brompton and Hareﬁeld Trust.
Data analysis and statistics
Data are presented as mean±SEM and statistical signiﬁcance
was assumed when p<0.05. N numbers and statistical tests used
were the Mann–Whitney test when two datasets were compared
and Kruskal–Wallis ANOVA followed by Dunn’s multiple com-
parison for three or more datasets. The speciﬁc test used is indi-
cated in the ﬁgure legends.
RESULTS
Role of EP receptors in murine respiratory models of airway
inﬂammation
Wild type mice challenged with the various disease relevant
stimuli evoked the expected inﬂammatory responses associated
with increases in a particular cell type. In particular, increases in
airway neutrophils were observed in the LPS and cigarette
smoke models and eosinophils after antigen challenge (ﬁgure 1).
In the LPS and allergen models, inﬂammatory cell inﬁltration
was signiﬁcantly increased in the EP4 receptor (Ptger4−/−) KO
mice (with no change in EP1–3 KO mice) compared with the
wild type control, suggesting a protective role for EP4 receptor
activation (ﬁgure 1). To determine if this phenomenon was
restricted to these inﬂammatory stimuli, we compared inﬂamma-
tory cell inﬁltration into the airway following cigarette smoke
challenge and found that absence of the EP4 receptor appeared
to enhance the inﬂammatory response (ﬁgure 1E).
The EP4 KO mice, of necessity, were on a different genetic
background to the other three KO lines.10 This difference in
genetic background between the studies with EP1–3 and EP4
receptor KO mice could conceivably complicate the data inter-
pretation. Thus, in order to provide evidence that functional
changes were associated with the ‘disease phenotype’ and not
speciﬁc to the genetic background of the mice, we assessed EP
receptor expression in the allergen and LPS models in mice bred
on a pure C57bl/6 background. While we could not detect a
robust temporal change in the levels of EP1–3 receptor mRNA,
EP4 receptor mRNA levels were signiﬁcantly increased across a
number of time points in both inﬂammatory models (see online
supplementary ﬁgures S1 and S2).
Anti-inﬂammatory role of EP receptors in cell-based assay
systems
In three different disease relevant in vivo models of airway
inﬂammation we found that the inﬂammatory response was
increased in EP4 receptor KO mice, suggesting an anti-
inﬂammatory role for endogenous prostaglandins via activation
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of EP4 receptors. In order to perform more in-depth investiga-
tions using pharmacological tools without the appropriate phar-
macokinetic proﬁle for in vivo studies and in order to provide
translational data, we performed studies in human cell-based
assays. To investigate the anti-inﬂammatory potential of PGE2,
we examined the effect of exogenously added PGE2 on
Figure 1 Role of EP receptors in murine respiratory models. (A, B) Eosinophils in lavage ﬂuid from mice sensitised and challenged with ovalbumin
(OVA), wild type controls versus EP1–3 knockout (KO) mice (A) or wild type controls versus EP4 KO mice (B). (C, D) Neutrophils in lavage ﬂuid from
mice challenged with lipopolysaccharide (LPS), wild type controls versus EP1–3 KO mice (C) or wild type controls versus EP4 KO mice (D). (E)
Neutrophils in lavage ﬂuid from mice exposed to cigarette smoke, wild type controls versus EP4 KO mice. Data shown are mean±SEM (n=8).
#Statistical signiﬁcance between control challenge and stimulation (p<0.05, Mann–Whitney test). *Statistical signiﬁcance between wild type and KO
mice (p<0.05, Mann–Whitney test).
Figure 2 Effect of prostaglandin E2 (PGE2) on cytokine release in cell-based assays. Effect of increasing concentrations of PGE2 on levels of tumour
necrosis factor α (TNFα) (A, C) and interleukin 6 (IL-6) (B, D) in culture medium from mouse ( J774; A, B) and human (THP-1; C, D) THP-1 cells
stimulated with vehicle (saline) or lipopolysaccharide (LPS; 0.1 μg/mL). Data shown are mean±SEM of three experimental runs performed in
duplicate. #Statistical signiﬁcance between vehicle and stimulation (p<0.05, Mann–Whitney test). *Statistical signiﬁcance between stimulation and
PGE2-treated cells (p<0.05, Kruskal–Wallis ANOVA followed by Dunn’s multiple comparison test).
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inﬂammatory responses to one of the stimuli used in the murine
model, namely LPS. All experiments were performed in the pres-
ence of a broad spectrum cyclo-oxygenase inhibitor to block
endogenous prostanoid production which may complicate data
interpretation. PGE2 produced a concentration-related inhibition
of LPS-induced cytokine production in mouse and human mono-
cytes (ﬁgure 2). To investigate which receptor(s) were central to
the anti-inﬂammatory effect seen with PGE2, we repeated the
study using selective EP agonists and found that only the EP4
receptor agonist (ONO-AE1-329) modulated cytokine levels at
concentrations commensurate with the reported nanomolar
potency of this ligand at the EP4 receptor (ﬁgure 3D, H). In a
parallel experiment, the same EP receptor agonists did not
trigger cytokine release under non-stimulated conditions (see
online supplementary ﬁgure S3). Interestingly, EP4 receptor
mRNA expression was the predominant EP receptor subtype
expressed at the mRNA level in these cells and primary human
alveolar macrophages (see online supplementary ﬁgure S4).
These data suggest that the EP receptor expression proﬁle and
the predominance of EP4 explains why the anti-inﬂammatory
activity of PGE2 is mediated via the EP4 receptor.
To conﬁrm that the EP4 receptor is central to the anti-
inﬂammatory properties of PGE2, we performed experiments in
the presence of selective EP2 and EP4 receptor antagonists
(PF-04418948 and ONO-AE3-208, respectively) and focused
on tumour necrosis factor α (TNFα) production as an example
cytokine. The data clearly show that the EP4 receptor antagonist
blocks the anti-inﬂammatory activity of both the selective EP4
receptor agonist and PGE2 itself (ﬁgure 4C, D), with no effect
of the EP2 receptor antagonist.
In order to investigate whether the production of TNFα was
regulated at the transcriptional or translational level, we had to
Figure 3 Effect of selective EP receptor agonists on cytokine release. Effect of increasing concentrations of EP receptor agonists (EP1: ONO-D1-004,
EP2: ONO-AE1-259, EP3: ONO-AE-248, EP4: ONO-AE1-329) on levels of tumour necrosis factor α (TNFα) (A–D) and interleukin 6 (IL-6) (E–H) in
culture medium from human (THP-1) monocytes stimulated with vehicle (saline) or lipopolysaccharide (LPS; 0.1 μg/mL). Data shown are mean±SEM
of three experimental runs performed in duplicate. #Statistical signiﬁcance between vehicle and stimulation (p<0.05, Mann–Whitney test).
*statistical signiﬁcance between stimulation and agonist treated cells (p<0.05, Kruskal–Wallis ANOVA followed by Dunn’s multiple comparison test).
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determine a suitable time point to measure mRNA production.
The 2 h time point was selected to measure mRNA and protein
production was assessed 22 h after stimulation (ﬁgure 5A). The
EP4 receptor agonist modulated both the mRNA and protein
levels, which suggests that activation of the receptor modulates
cytokine production at the transcriptional level (ﬁgure 5C, D).
To explore the signalling mechanisms involved, we investigated
the effects of mimicking proposed EP4 receptor signalling involv-
ing the AC-PKA/EPAC pathways. The AC activator, but not its
negative control (1,9 dideoxyforskolin, which shares many of the
activities of forskolin but does not activate AC), caused a
concentration-related inhibition of cytokine production which
was of a similar magnitude to the EP4 receptor agonist (ﬁgure
6A, B). Similarly, an activator of PKA, but not EPAC, mirrored
the effect of the EP4 receptor agonist (ﬁgure 6C, D). In order to
determine if this proposed pathway was indeed triggered by acti-
vating the EP4 receptor, we employed a selective PKA blocker.
The PKA inhibitor caused a concentration-related block of the
anti-inﬂammatory properties of both a PKA activator and the EP4
receptor agonist (ﬁgure 7A, B). Finally, to demonstrate this
Figure 4 Effect of selective EP receptor antagonists on inhibitory effect of prostaglandin E2 (PGE2) and EP4 agonist-induced cytokine release. Effect
of EP4 receptor agonist (ONO-AE1-329, 1 nM) (A, C) or PGE2 (1 nM) (B, D) in the presence of increasing concentrations of EP2 (PF-04418948) or EP4
(ONO-AE3-208) receptor antagonists on tumour necrosis factor α (TNFα) levels in culture medium from human (THP-1) monocytes stimulated with
vehicle (saline) or lipopolysaccharide (LPS; 0.1 μg/mL). Data shown are mean±SEM of three experimental runs performed in duplicate. #Statistical
signiﬁcance between vehicle and stimulation (p<0.05, Mann–Whitney test). *Statistical signiﬁcance between stimulation and agonist treated cells
(p<0.05, Kruskal–Wallis ANOVA followed by Dunn’s multiple comparison test).
Figure 5 Assessing the effect of EP4 receptor activation on transcription and translation of tumour necrosis factor α (TNFα). TNFα mRNA (A) and
protein production (B) following treatment with vehicle (saline) or lipopolysaccharide (LPS; 0.1 μg/mL) over time in the culture medium of human
(THP-1) monocytes. (C) TNFα mRNA measured 2 h post stimulation and (D) protein measured 22 h post stimulation in the presence of EP4 receptor
agonist (ONO-AE1-329). Data shown are mean±SEM of three experimental runs performed in duplicate. #Statistical signiﬁcance between vehicle and
stimulation (p<0.05, Mann–Whitney test). *Statistical signiﬁcance between stimulation and agonist treated cells (p<0.05, Mann–Whitney test).
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pathway was active in primary cells, we repeated the observation
in human alveolar macrophages (ﬁgure 7C).
DISCUSSION
Current anti-inﬂammatory therapy for asthma and COPD is
focused on the use of glucocorticoids, but their efﬁcacy is
limited in COPD and in certain patient subgroups with asthma.
Furthermore, there are signiﬁcant patient compliance issues and
safety concerns associated with their long-term use. Existing
treatment of both diseases is focused on combination therapies
which include a bronchodilator together with the glucocorticoid
anti-inﬂammatory. Therefore, a single treatment with both anti-
inﬂammatory and bronchodilator potential would be a preferred
therapeutic option, especially if it could be developed as an oral
medication to avoid compliance issues.
The beneﬁcial properties of PGE2 in the lung have long been
recognised, but irritancy issues and the poor pharmacokinetic
proﬁle of endogenous bioactive lipid mediators mean that these
properties are yet to be fully harnessed. Previous studies have
started to deﬁne the EP receptors associated with the beneﬁcial
and undesirable properties associated with PGE2 to identify a
receptor subtype which could be targeted for the development
of a therapeutic. For example, EP4 receptor activation has been
proposed to be involved in PGE2-induced bronchodilation of
human airway smooth muscle and EP3 receptor activation to
trigger airway sensory nerves producing unwanted reﬂexes such
as cough.8 9 The aim of this study was to begin to explore
which receptor(s) are required for the airway anti-inﬂammatory
properties of PGE2.
The initial body of work was performed in three in vivo
murine models with distinct phenotypes (modelling innate,
allergic and COPD-like inﬂammation) and demonstrated that
EP4 receptor KO mice had an enhanced cellular inﬂammation,
suggesting an endogenous anti-inﬂammatory role for PGE2
acting on the EP4 receptor. Supporting these data was the obser-
vation that EP4 receptor gene expression was increased in the
lungs after disease relevant challenges in standard (C57bl/6)
wild type mice, suggesting that this observation was not speciﬁc
to the genetic background of the mice used in the EP4 compara-
tor studies. Consistent with these ﬁndings are the facts that most
immune cell types have been reported to express EP4 recep-
tors,7 19 20 and EP4 receptor activation reduces transendothelial
migration of eosinophils and neutrophils21 22 and induces sup-
pression in a murine model of aspirin-triggered allergic hyperre-
sponsiveness.23 In contrast to these observations, a protective
role for EP3 receptor activation has been reported in a murine
asthma model.24 Although a beneﬁcial role for the EP3 receptor
is not supported in studies demonstrating that PGE2—but not
the EP3 receptor agonist sulprostone—exhibits anti-
inﬂammatory effects in an allergic murine model, and in other
studies suggesting that EP3 receptor activation is chemotactic for
lung mast cells.25 Alternatively, other studies have reported that
EP2 receptor activation inhibits asthma-related eosinophilic traf-
ﬁcking.26 27 Although studies exist supporting a role for alterna-
tive receptors in mediating the anti-inﬂammatory effects of
PGE2, often the study investigators have not had the opportun-
ity to use the wide range of selective pharmacological tools and
KO mice that we have been able to employ here. Furthermore,
the majority of the published literature regarding the anti-
inﬂammatory role of PGE2 is in agreement with our data sug-
gesting a role for the EP4 receptor.
To provide further conﬁrmatory data regarding the role of
the EP4 receptor and to investigate the downstream signalling
pathway, we used cell-based systems which are more amenable
to study and where data interpretation is not limited by the
pharmacokinetic limitations of tool compounds. This approach
also enabled translation of ﬁndings in murine systems to human
cells. Monocyte/macrophage cell types were used as the preva-
lent cell in the airway and the cell type most likely to have a
common role in all three inﬂammatory responses that were
modelled in the mouse. Furthermore, previous studies had
demonstrated EP4 receptor gene expression in murine macro-
phages,28 the murine monocyte cell line J774 cells29 and human
lung macrophages.20 30 In these experiments, using one of the
stimuli used in the model systems (endotoxin, LPS), PGE2 also
had an anti-inﬂammatory role demonstrated as the inhibition of
Figure 6 EP4 receptor activation and downstream signalling pathways. The effect of vehicle, adenylyl cyclase (AC) activator (A), AC activator
negative control (B), cAMP-dependent protein kinase (PKA) activator (C), or exchange proteins activated by cAMP (EPAC) activator (D) on tumour
necrosis factor α (TNFα) release from human (THP-1) monocytes stimulated with vehicle (saline) or lipopolysaccharide (LPS; 0.1 μg/mL). The EP4
receptor agonist (ONO-AE1-329, 1 nM) was included as a positive control. Data shown are mean±SEM of three experimental runs performed in
duplicate. #Statistical signiﬁcance between vehicle and stimulation (p<0.05, Mann–Whitney test). *Statistical signiﬁcance between stimulation and
agonist treated cells (p<0.05, Kruskal–Wallis ANOVA followed by Dunn’s multiple comparison test).
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cytokine release via activation of the EP4 receptor. These data
are consistent with previous studies that have reported a similar
role for the EP4 receptor in a diverse range of cell-based
assays.19 20 29 31 32 Interestingly, we did not observe an anti-
inﬂammatory role for the EP2 receptor, as suggested by other
studies. In addition, although we failed to note any
pro-inﬂammatory effects of PGE2, it has been reported to
increase levels of inﬂammatory mediators such as vascular endo-
thelial growth factor through both EP2 and EP4 receptors.
33
To investigate how activation of the EP4 receptor attenuates
cytokine production, we probed the reported signalling mechan-
isms. EP4 receptors signal via activation of Gαs and AC and a
subsequent increase in intracellular cAMP which can then acti-
vate PKA or EPAC.7 While others have suggested different sig-
nalling mechanisms such as EP4 receptor-associated protein
(p105/NF-kB) and Gαi (PI3K/PKC),32 34 35 many report that
the cAMP/PKA axis is central to the response.7 In our cell
systems we demonstrated that the anti-inﬂammatory actions of
PGE2 and the speciﬁc EP4 receptor agonist were mimicked by
AC and PKA activators, but not an EPAC activator, and blocked
by a PKA inhibitor. Furthermore, cytokine production was sup-
pressed at the mRNA level, presumably by halting its transcrip-
tion or by increasing mRNA degradation.
In conclusion, these ﬁndings present a convincing dataset that
supports the hypothesis that the anti-inﬂammatory activity of
PGE2 is mediated via activation of the EP4 receptor and that
this mechanism is capable of suppressing airway inﬂammation
that is triggered via an array of stimuli. We have shown that EP4
receptor KO mice have enhanced inﬂammation after innate,
allergic and COPD-like conditions, and cytokine production
from primary human alveolar macrophages is attenuated by an
EP4 agonist in a cAMP/PKA-dependent manner. We suggest that
an EP4 receptor agonist with an appropriate pharmacokinetic
proﬁle would harness the beneﬁcial properties of PGE2 and
make an effective anti-inﬂammatory and bronchodilator for the
treatment of respiratory diseases such as asthma and COPD.
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